Human Molecular Genetics, Vol 6, 913-919, Copyright © 1997 by Oxford University Press
T Habuchi, O Yoshida and MA Knowles
Loss of heterozygosity (LOH) on chromosome 9q is the most frequent genetic
alteration in transitional cell carcinoma (TCC) of the bladder, implicating
the presence of a tumour suppressor gene or genes on 9q. To define the
location of a tumour suppressor locus on 9q in TCC, we screened 156 TCCs of
the bladder and upper urinary tract by detailed deletion mapping using 31
microsatellite markers on 9q. Partial deletions of 9q were found in 10 TCCs
(6%), and LOH at all informative loci on 9q was found in 77 TCCs (49%). In
five low grade superficial bladder tumours, the partial deletion was
localized to D9S195 located at 9q32-33, with retention of heterozygosity at
all other informative loci including D9S103, D9S258, D9S275 and GSN. We
constructed a yeast artificial chromosome (YAC) contig covering the deleted
region in these five tumours and placed another four unmapped
microsatellite markers on this contig map. Using these markers, we further
defined the common deleted region to the interval between D9S1848 and
AFMA239XA9. The region is covered by a single YAC (852e11), whose size is
estimated to be 840 kb. Our data should expedite further fine mapping and
identification of the candidate tumour suppressor gene at 9q32-33.
ARTICLES
A novel candidate tumour suppressor locus at 9q32-33 in bladder cancer: localization of the candidate region within a single 840 kb YAC
Molecular Genetics Laboratory, Marie Curie Research Institute, Surrey, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Knowles Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis, March 1, 2006; 27(3): 361 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Chapman, P. Harnden, P. Chambers, C. Johnston, and M. A. Knowles Comprehensive Analysis of CDKN2A Status in Microdissected Urothelial Cell Carcinoma Reveals Potential Haploinsufficiency, a High Frequency of Homozygous Co-deletion and Associations with Clinical Phenotype Clin. Cancer Res., August 15, 2005; 11(16): 5740 - 5747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Dabelsteen and S. Gao ABO Blood-group Antigens in Oral Cancer Journal of Dental Research, January 1, 2005; 84(1): 21 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M A Knowles What we could do now: molecular pathology of bladder cancer Mol. Pathol., August 1, 2001; 54(4): 215 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Knuutila, Y. Aalto, K. Autio, A.-M. Bjorkqvist, W.'e. El-Rifai, S. Hemmer, T. Huhta, E. Kettunen, S. Kiuru-Kuhlefelt, M. L. Larramendy, et al. DNA Copy Number Losses in Human Neoplasms Am. J. Pathol., September 1, 1999; 155(3): 683 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hartmann, K. Moser, M. Kriegmair, A. Hofstetter, F. Hofstaedter, and R. Knuechel Frequent Genetic Alterations in Simple Urothelial Hyperplasias of the Bladder in Patients with Papillary Urothelial Carcinoma Am. J. Pathol., March 1, 1999; 154(3): 721 - 727. [Abstract] [Full Text] [PDF]
|
|